BioCentury
ARTICLE | Clinical News

Subcutaneous semaglutide: Phase IIIa data

September 28, 2015 7:00 AM UTC

The open-label, international Phase IIIa SUSTAIN 3 trial in 813 Type II diabetics showed that once-weekly 1 mg subcutaneous semaglutide met the primary endpoint of reducing mean HbA1c from baseline to...